

**Suppl. 1: Volcano plot and clustering heat map analysis of 757 differentially regulated probe sets. A)** The scatter plot represents all tested probe sets with their statistical significance of differential expression as  $-\log_{10}$  of p-value (y-axis) and their extend of differential expression between normoxia and hypoxia as  $\log_2$  fold change (x-axis). The horizontal dashed line separates probe sets according to their p-values (0.05) and the vertical dashed lines according to their mean M =  $\log_2$  fold change (-1; +1). **B)** The heat map reflects gene expression values in normoxia vs. hypoxia. The colour intensity of single probes stands for their normalized expression, where blue represents low and red high expression respectively. Each column (1-3) represents one separate experiment, each row one of the 757 probe sets.



↑ set	Gene symbol	BHp	FC
1.	ENO2	6,12E-06	177,28
2.	PFKP	2,92E-05	77,66
3.	PFKFB4	8,95E-05	56,37
4.	SPAG4	1,15E-02	50,76
5.	NDRG1	2,16E-04	47,62
6.	LOC154761	2,40E-04	43,04
7.	TUBB2B	3,59E-04	40,79
8.	FSIP1	7,39E-04	38,73
9.	ANKRD37	1,77E-04	37,94
10.	SERPINE1	8,26E-03	37,36
11.	TAC1	1,13E-04	35,01
12.	ADORA2B	1,59E-04	33,44
13.	FBXO16	1,17E-03	31,30
14.	PPP1R3C	1,16E-05	26,69
15.	FAM57A	7,66E-04	26,66
16.	MT1G	1,85E-02	25,12
17.	ZNF395	7,31E-04	24,27
18.	SLC2A1	7,42E-03	23,26
19.	ARG2	9,65E-03	22,38
20.	ANGPTL4	1,54E-02	22,26
21.	LEP	8,18E-03	21,12
22.	MT1X	2,21E-02	21,11
23.	MT1F	2,47E-02	20,87
24.	C7orf44	1,37E-02	20,51
25.	DHRS13	5,31E-03	20,18
26.	PPFIA4	2,20E-02	19,86
27.	MT1E	2,75E-02	19,50
28.	STC1	7,01E-03	19,18
29.	RORA	1,14E-02	19,17
30.	C16orf74	6,36E-04	18,95
31.	KDM3A	8,95E-05	18,52
32.	STC2	2,32E-03	18,40
33.	MT1H	1,04E-02	16,46
34.	MT3	3,83E-02	16,31
35.	BLNK	2,95E-04	16,11
36.	ATF3	7,94E-03	16,09
37.	OR51F2	2,36E-03	15,42
38.	MAFF	6,87E-04	15,07
39.	SLC16A3	1,62E-02	14,72
40.	DUSP5	1,39E-02	14,63
41.	BCAR1	9,82E-03	14,62
42.	LOXL3	1,59E-04	14,59
43.	APLN	1,84E-03	14,30
44.	CDC6	3,06E-02	14,28
45.	C16orf81	3,17E-02	13,70
46.	MT2A	3,08E-03	13,64
47.	RAB33A	1,28E-03	13,47
48.	ERO1L	2,50E-03	13,43
49.	E2F7	8,95E-05	13,16
50.	NEDD4L	6,47E-03	12,85

↑ set	Gene symbol	BHp	FC
51.	RNF19B	2,19E-02	12,56
52.	SFXN3	4,79E-03	12,45
53.	C9orf25	1,15E-04	12,31
54.	MT1P2	2,04E-02	12,25
55.	FUT11	1,20E-03	12,22
56.	WDR5B	3,02E-04	12,20
57.	SLC2A3	2,87E-02	12,13
58.	LIPG	4,38E-02	12,13
59.	PLA2G6	7,39E-04	12,07
60.	TMEM184B	7,39E-04	12,07
61.	TET1	2,36E-03	11,77
62.	KLF7	1,44E-02	11,72
63.	ADSSL1	2,84E-04	11,67
64.	AKAP13	1,32E-02	11,64
65.	VEGFA	1,52E-03	11,15
66.	MXI1	1,41E-04	11,13
67.	JUN	2,16E-02	10,71
68.	TRIB3	1,07E-02	9,92
69.	MGAT5	1,84E-04	9,69
70.	DOK5	3,71E-02	9,47
71.	INSIG2	5,86E-03	9,28
72.	TBC1D8	1,66E-03	9,08
73.	FOSL2	2,22E-03	8,91
74.	KCNE4	1,62E-02	8,87
75.	SAP30	3,41E-04	8,81
76.	SLC6A8	8,82E-04	8,74
77.	EGLN1	1,05E-03	8,61
78.	FLJ41603	4,91E-02	0,40
79.	RAB20	2,11E-02	8,15
80.	JAM2	3,65E-02	8,04
81.	SLC7A5	7,13E-03	8,03
82.	INHBE	1,32E-02	8,01
83.	P4HA2	2,04E-03	7,76
84.	RFX2	3,98E-03	7,72
85.	WDR73	1,84E-04	7,69
86.	FANCE	7,41E-03	7,64
87.	PIOD2	3,99E-02	7,64
88.	PNMA2	9,40E-03	7,52
89.	FLNB	4,33E-03	7,46
90.	HMOX1	4,76E-02	7,44
91.	MAPK7	1,21E-02	7,34
92.	MYO10	1,83E-02	7,32
93.	MTP18	9,59E-03	7,12
94.	FGF11	2,40E-04	7,06
95.	IL15	4,44E-02	6,70
96.	C9orf30	2,47E-02	6,47
97.	TMEFF1	2,47E-02	6,47
98.	METRNL	3,87E-03	6,39
99.	KBTBD9	1,88E-02	6,39
100.	HTRA3	2,68E-03	6,35

↑ set	Gene symbol	BHp	FC
101.	YEATS2	2,92E-05	6,35
102.	PHLDA1	2,43E-02	6,34
103.	LPCAT1	1,35E-02	6,28
104.	TGIF1	4,62E-03	6,23
105.	FLJ35024	2,75E-02	6,13
106.	EFNB2	3,65E-02	6,11
107.	PPP1R15A	3,77E-02	6,02
108.	RAB27A	2,99E-02	5,96
109.	LOX	2,26E-02	5,92
110.	GYS1	1,95E-04	5,86
111.	GTPBP2	9,62E-03	5,84
112.	PDE4C	1,28E-03	5,81
113.	PTGS2	4,73E-02	5,75
114.	DDIT4L	4,28E-02	5,68
115.	ALDOC	1,26E-03	5,57
116.	ETS1	1,42E-02	5,53
117.	PLEKHA2	1,07E-03	5,45
118.	MGC42105	2,55E-02	5,43
119.	NXN	2,23E-03	5,42
120.	PPP2R5B	2,32E-02	5,40
121.	ETV5	1,26E-02	5,33
122.	SHB	7,93E-04	5,33
123.	CLEC4C	3,67E-02	5,19
124.	SAMD4A	1,50E-02	5,14
125.	ARSA	3,14E-02	5,09
126.	PKD3	8,06E-04	5,07
127.	PANX1	1,15E-02	5,07
128.	DDIT4	2,40E-04	5,06
129.	SCAI	9,52E-03	5,04
130.	AMPD3	4,25E-02	4,99
131.	WDR54	4,75E-04	4,96
132.	FAM13A	2,28E-02	4,94
133.	ALKBH5	3,06E-04	4,92
134.	CAMTA2	3,72E-02	4,92
135.	PTGES	4,96E-02	4,91
136.	LGALS3	2,58E-02	4,90
137.	ARAP1	2,29E-03	4,88
138.	MTSS1	2,10E-02	4,86
139.	CNOT8	1,94E-03	4,82
140.	AGAP1	2,42E-03	4,81
141.	RASSF5	7,41E-03	4,77
142.	SCARB1	8,37E-03	4,74
143.	RNF24	7,50E-03	4,73
144.	SIK1	1,55E-02	4,69
145.	SLC16A1	8,54E-03	4,69
146.	FAM26F	3,28E-02	4,61
147.	C4orf47	2,07E-02	4,58
148.	C3orf58	2,35E-02	4,51
149.	MAP3K8	2,85E-02	4,50
150.	DUSP3	1,47E-02	4,49

↓ set	Gene symbol	BHp	FC
1.	ELOVL3	8,95E-05	0,05
2.	STX11	1,19E-02	0,05
3.	SERPINB9	3,21E-04	0,05
4.	ATL2	1,05E-02	0,12
5.	SGK2	1,66E-03	0,12
6.	HSPH1	2,30E-02	0,13
7.	DHFRL1	1,73E-02	0,13
8.	DHFRP1	1,73E-02	0,13
9.	TFRC	2,91E-02	0,14
10.	SDPR	2,03E-02	0,14
11.	LOC153346	6,64E-03	0,15
12.	RTN4IP1	8,86E-03	0,16
13.	LOC100132418	1,32E-02	0,16
14.	HK2	5,16E-03	0,17
15.	TMEM164	1,16E-02	0,17
16.	ELMOD3	2,13E-02	0,18
17.	FASTKD1	4,53E-02	0,18
18.	GLUD1	1,71E-03	0,18
19.	GLUD2	1,71E-03	0,18
20.	PHF15	2,11E-02	0,18
21.	KBTBD6	3,89E-02	0,19
22.	ATF7IP	1,49E-02	0,19
23.	RP3-398D13.1	2,06E-02	0,20
24.	SUOX	9,77E-03	0,20
25.	PXMP4	6,65E-03	0,21
26.	TIMM8A	2,10E-03	0,21
27.	NUP98	4,06E-03	0,21
28.	TMCM37	4,44E-02	0,21
29.	BPNT1	2,56E-03	0,21
30.	CDC23	4,24E-02	0,22
31.	SLC25A12	3,42E-02	0,22
32.	KCNB1	2,66E-02	0,22
33.	ADAMTS3	2,33E-03	0,23
34.	UBE2T	2,02E-02	0,23
35.	SLC11A2	7,54E-03	0,23
36.	PDP2	2,31E-02	0,24
37.	TOMM40I	1,45E-03	0,25
38.	HSPBPAP1	3,83E-02	0,25
39.	PIGU	2,59E-03	0,25
40.	ZBED1	1,49E-02	0,26
41.	C14orf104	7,93E-04	0,26
42.	NAPEPLD	5,77E-04	0,26
43.	FUBP1	3,74E-03	0,27
44.	MANSC1	4,26E-02	0,27
45.	FASTKD5	8,41E-03	0,27
46.	RUVBL1	4,03E-02	0,27
47.	PPIL1	3,47E-02	0,28
48.	SCFD2	1,51E-02	0,28
49.	PBX1	7,24E-03	0,28
50.	C1orf131	3,71E-03	0,28

**Suppl. 3: The top 150 up- and top 50 downregulated genes in SGBS adipocytes after 16h of hypoxia.** Members of the upregulated (↑) as well as downregulated (↓) gene set were ranked according to the genes' FC. P-values (BHp) have been calculated according to Benjamini and Hochberg.

**Following sequences for the primers were used:**

**ENO2:** fwd 5'-AGGACACATTCATTGCTGAC-3' and rev 5'-CCCAGCTCTTCCTCAATTC-3', binding exons 10 to 12, and as a control (ENO2\*) fwd 5'-CATGTGGCTGTAGATCCCAAG-3' and rev 5'-ACGCAGGCTTCAGTGAGTACAC-3', binding in exon 12, PFKP: fwd 5'-CGATGATTCCATTTGTGTGC-3' and rev 5'-AGCTTGAGCCACCACTGTTC-3',

**PFKFB4:** fwd 5'-CTCCTGTGGCATATGGTTG--3' and rev 5'-AGGTCTTGAGATGTCCACG 3',

**ALDOC:** fwd 5'-CTGCCACTGAGGAGTTCATC-3' and rev 5'-CTCCACCATCTTCTCCACTG-3',


**TBP:** fwd 5'-GGGAGCTGTGATGTGAAGTTT-3' and rev 5'-AAGGAGAACAATTCTGGGTTTG-3',

**ATF3:** fwd 5'-GTCTCTGCCTCGGAAGTGAG-3' and rev 5'-TGACAAAGGGCGTCAGGT-3',

**JUN:** fwd 5'-ACAGAGCATGACCCTGAACC-3' and rev 5'-CGTTGCTGGACTGGATTATCA-3',

**FOSL2:** fwd: 5'-CGGATCATGTACCAGGATTA-3' and rev TGAGCCAGGCATATCTACC-3', and


**KLF7:** fwd 5'-CTTCTCAGCTTTACCATCCCTG-3' and rev 5'-GGAAGCGTGGAGGAAACAG-3'.



**Suppl. 4: Primer sequences and alternate qPCR data for ENO2.** QPCR primers were specific for ENO2, not for ENO1 due to six mismatches. There was a distinct melting curve and no second product detectable. Nevertheless, we repeated the qPCR with a second primer pair (ENO2\*) binding the same sequence parts as used by the affymetrix probe set 201313\_at for ENO2 and which does not bind ENO1. The results of both qPCRs were comparable.

### Immunoblotting

For preparation of nuclear SGBS extracts, NE-PER® Nuclear and Cytoplasmic Extraction Reagents (Pierce Biotechnology, IL, USA) containing a protease inhibitor cocktail and a phosphatase inhibitor cocktail were used. Total protein concentration was determined using the protein assay reagent (Bio-Rad Laboratories, Munich, Germany). Extracts were dissolved in 4x SSB loading buffer containing 20%  $\beta$ -mercaptoethanol and boiled. Fifteen micrograms of nuclear extracts were separated by SDS-PAGE electrophoresis and then transferred to nitrocellulose membrane (Schleicher & Schuell, Dassel, Germany). Membranes were blocked and incubated with primary antibodies specific for HIF-1 $\alpha$  (R&D Systems, MN, USA) and Topoisomerase I (Cell Signaling, Frankfurt, Germany), washed and then incubated with horseradish-peroxidase-conjugated anti-mouse and anti-rabbit secondary antibodies (GE Healthcare, Buckinghamshire, UK), respectively. Specific bands were visualized by enhanced chemiluminescence reagent (ECL Plus; GE Healthcare) and analyzed in an AutoChemi detection system (UVP, Cambridge, UK).



**Suppl. 5: Effect of HIF-1a Inhibitor on protein levels in SGBS adipocytes under hypoxic cultivation.** Fully differentiated SGBS adipocytes were incubated under hypoxic (1% O<sub>2</sub>) or under normoxic conditions in presence of indicated concentrations of the HIF-1 a inhibitor CAY10585 for up to 16h. Protein levels of HIF-1a and topoisomerase 1 (Topo1) as a control were examined by immunoblotting.

	Matrix sequence	Matrix name	Gene symbol	Yes/No	P-value	Positions	Matrix match	Matched sequence
ENO2	1.	V\$AP1_01	FOS; FOSB; FOSL1, -2; JUN; JUNB, -D	inf	2.00E-03	-131(-)	0.986	tccTGACTcatcg
	2.	V\$AP1_Q2_01	FOS; FOSB; FOSL1, -2; JUN; JUNB, -D	inf	2.00E-03	-127(+)	1.000	TGACTcatcggg
	3.	V\$AP1_C	ATF2; FOS; FOSB; FOSL1, -2; JUN; JUNB, -D; SMAD3; TGIF1	inf	2.00E-03	-128(-)	1.000	cTGACTcat
	4.	V\$NF1_Q6	NFIC	489.00	4.10E-03	-493(+)	0.990	cgtgggtgagaGCCAAga
	5.	V\$NF1_Q6_01	NFIC	244.50	6.10E-03	-493(+)	0.992	qtgqgtqaqaGCCAAqa
	6.	V\$E2_Q6_01	n/a	195.60	8.69E-05	-181(-)	0.917	caccctcgtCGGTc
						-183(+)	0.918	tcCACCCtcgtcggtc
	7.	V\$HIF1_Q5	HIF1A	163.00	8.10E-03	-154(+)	0.967	cgtACGTGcgcc
	8.	V\$BACH1_01	BACH1, -2	163.00	8.10E-03	-131(-)	0.936	ctcctgACTCATcgg
	9.	V\$E2_Q6	n/a	163.00	8.10E-03	-182(+)	0.965	ccaccclcgLCCGTcc
	10.	V\$HIF2A_01	EPAS1	163.00	8.10E-03	-153(+)	0.997	gtACGTGcgc
11.	V\$E2_01	n/a	75.23	4.30E-04	-182(+)	0.958	ccaccctcgtCGGTcc	
					-182(-)	0.925	cCACCCtcgtcggtcc	
PFKP	1.	V\$HIF1_Q5	HIF1A	244.50	6.10E-03	514(+)	0.987	cggACGTGcgcc
	2.	V\$HIF1_Q3	HIF1A	244.50	6.10E-03	513(+)	0.975	ccggACGTGcggtc
	3.	V\$MYOD_Q6_01	ARID5B; ASCL1; MYF5; MYF6; MYOD1; MYOG; TCF12, -3, -4	163.00	8.10E-03	130(-)	0.976	ctgccccACCTGtggcgc
PFKFB4	1.	V\$AP4_01	TFAP4	inf	2.00E-03	240(-)	0.949	gggaccccAGCTGtttct
	2.	V\$TFE_Q6	MITF; TFE3; TFEB, -C	489.00	4.10E-03	366(-)	1.000	tcACATGa
	3.	V\$YY1_01	YY1	489.00	4.10E-03	81(+)	0.992	ggagGCCATttttgaag
	4.	V\$BACH1_01	BACH1, -2	244.50	6.10E-03	256(+)	0.943	ctgaTGAGTcacact
	5.	V\$STAT_Q6	STAT1, -2, -3, -4, -5A, -5B, -6	244.50	6.10E-03	569(-)	0.994	tccCAGAAtggtg
	6.	V\$PAX6_Q2	PAX6	244.50	6.10E-03	276(-)	0.852	aagTTCCAggtcct
	7.	V\$NRF2_Q4	BACH1, -2, MAF; MAFB, -F, -G, -K; NFE2; NFE2L1, -2, -3	163.00	8.10E-03	256(+)	0.945	ctgatgAGTCAca
	8.	V\$AP2ALPHA_03	TFAP2A, -B, -C	97.80	2.71E-04	436(+)	0.936	ggagcctgAGGCCTa
						436(-)	0.936	ggAGCCTgaggccta
	9.	V\$AP1_01	FOS; FOSB; FOSL1, -2; JUN; JUNB, -D	69.86	4.90E-04	257(+)	0.970	tgatgAGTCAcac
						257(-)	0.961	tgaTGAGTcacac
	10.	V\$AP1_C	ATF2; FOS; FOSB; FOSL1, -2; JUN; JUNB, -D; SMAD3; TGIF1	48.90	9.36E-04	259(+)	0.985	atgAGTCAc
							0.979	aTGAGTcac
	11.	V\$AP2ALPHA_02	TFAP2A, -B, -C	37.62	1.50E-03	436(+)	0.953	ggAGCCTgaggccta
					436(-)	0.952	ggagcctgAGGCCTa	
12.	V\$STAT5B_01	STAT1, -2, -3, -4, -5A, -5B, -6	27.17	2.80E-03	565(+)	0.905	agCTTCCcagaatgg	
					565(-)	0.939	agcttcccAGAATgg	
13.	V\$HSF1_01	HSF1, -2	26.43	2.90E-03	273(+)	0.990	AGAAAgttcc	
					273(-)	0.966	agaaaGTTC	
14.	V\$HSF2_01	HSF1, -2	23.85	3.60E-03	273(+)	0.986	AGAAAgttcc	
					273(-)	0.993	agaaaGTTC	
ALDOC	1.	V\$IPF1_Q4	PDX1	inf	2.00E-03	124(-)	0.969	gttCATTActtc
	2.	V\$ARNT_01	ARNT	inf	2.00E-03	252(-)	0.985	cccggCACGTggtaaa
	3.	V\$CMYC_02	MAX; MYC; MYCN	489.00	4.10E-03	254(-)	0.975	cggcACGTGgta
	4.	V\$NMYC_01	MAX; MYC; MYCN	489.00	4.10E-03	254(-)	0.998	cggCACGTggtta
	5.	V\$TEL2_Q6	ELF1, -2; ELK1, -4; ERG; ETS1, -2; ETV7; FLI1	489.00	4.10E-03	129(+)	1.000	ttACTTCCctg

**Suppl. 6: Transcription factor binding sites identified within ENO2-, PFKP-, PFKFB4-, and ALDOC-promotors.**

All sequences of matched PWMs within the cut-off-values as described in methods were ranked according to their “Yes/No” ratio (For ALDOC only top 5 of total 26 hits are displayed). The respective binding positions are indicated together with the matched sequence and the similarity score for the matrix match.

**A**

V\$HIF1\_Q5 [C=0.925500 N=1]  
 V\$NKX22\_01 [C=0.915500 N=2]  
 V\$SP1\_01 [C=0.885500 N=2]

and

V\$CEBPB\_01 [C=0.929500 N=3]  
 V\$PU1\_01 [C=0.901500 N=1]  
 V\$R\_01 [C=0.727500 N=2]

Model Fitness: 0.888  
 P-value: 4.9889e-15  
 FP: 3.89%  
 FN: 0.00%

**B**

V\$ALX4\_01 [C=0.576500 N=1]  
 V\$GATA1\_01 [C=0.969500 N=3]  
 V\$R\_01 [C=0.762500 N=2]  
 <- V\$BEL1\_B [C=0.783500] [3..30]  
 V\$MEIS1AHOXA9\_01 [C=0.812500]  
 -> [N=1]  
 <-V\$SOX9\_B1 [C=0.962500] [3..30]  
 V\$ZF5\_01 [C=0.886000]-> [N=1]

and

V\$DMRT4\_01 [C=0.721500 N=1]  
 V\$MYCMAX\_B [C=0.854500 N=3]  
 V\$P53\_01 [C=0.532500 N=3]  
 V\$USF\_01 [C=0.691500 N=3]  
 <-V\$AMEF2\_Q6 [C=0.642500] [3..30]  
 V\$USF\_02 [C=0.755500]-> [N=1]  
 <-V\$CDPCR1\_01 [C=0.710500] [3..30]  
 V\$MUSCLE\_INI\_B [C=0.755500]-> [N=2]  
 <-V\$DELTAEF1\_01 [C=0.888500] [3..30]  
 V\$TAXCREB\_02 [C=0.632000]-> [N=1]

Model Fitness: 0.862  
 P-value: 3.2212e-17  
 FP: 2.04%  
 FN: 0.00%

**C**

V\$AP2\_Q6 [C=0.888500 N=3]  
 V\$LYF1\_01 [C=0.738500 N=3]  
 V\$NMYC\_01 [C=0.842500 N=1]

and

V\$AP2\_Q6 [C=0.915500 N=1]  
 V\$XFD1\_01 [C=0.750500 N=1]

Model Fitness: 0.916  
 P-value: 3.4420e-14  
 FP: 1.23%  
 FN: 0.00%

**D**

V\$AHRHIF\_Q6 [C=0.931500 N=2]  
 V\$AP2GAMMA\_01 [C=0.965500 N=3]  
 V\$E2F\_01 [C=0.689500 N=1]  
 V\$E4F1\_Q6 [C=0.928000 N=3]  
 <-V\$COREBINDINGFACTOR\_Q6  
 [C=0.684500] [3..30]  
 V\$SATB1\_01 [C=0.779500]-> [N=2]  
 <-V\$PAX2\_01 [C=0.673500] [3..30]  
 V\$SOX9\_B1 [C=0.890500]-> [N=3]


and

V\$CDXA\_02 [C=0.801500 N=1]  
 V\$ETS1\_B [C=0.787500 N=1]  
 V\$ZF5\_01 [C=0.892500 N=3]  
 <-V\$DAX1\_01 [C=0.855500] [3..30]  
 V\$STAF\_01 [C=0.855500]-> [N=3]  
 <-V\$NKX3A\_01 [C=0.924000] [3..30]  
 V\$NRSF\_01 [C=0.701500]-> [N=3]

Model Fitness: 0.875  
 P-value: 3.4420e-14  
 FP: 1.23%  
 FN: 0.00%

**Suppl. 7: Promoter model calculated for the glycolysis and insulin pathway gene set.** Two models were generated to fit glycolysis involved ENO2, PFKP, PFKFB4, ALDOC, GPI, HK1, HK2, MPI, PFKL, PGK1, and TPI1 genes. One consisting solely of single matrices (A), the other also integrates matrix pairs (B). Two further models were generated to fit insulin pathway involved CBL, CREB1, GRB10, GYS1, INSR, MAP2K1, MAPK7, and NEDD4L genes, comprising only single matrices (C) or also pairs (D). The models were generated by the composite model analysis (CMA) as described in methods part. For each of the four specifications, the one with highest model fitness is displayed. All models consist of 2 groups, connected with a Boolean operator, harboring different single- or pairs of PWMs with their matrix cut-offs [C], the distance in pair ([n..n]) and the number of matrix matches expected in the module [N]. Overall model fitness, p-values as well as false positive (FP) and false negative (FN) frequencies of the models are indicated.





**Suppl. 8: Binding sites for HIF-family transcription factors within promoter regions of PPP1R3C and GYS1.** Schematic representation of matched PWMs (arrows) within the proximal promoters, representing the position of transcription factor binding sites. Start point of transcription is marked by a dashed line, the genome positions are indicated.

Gene set	Gene symbol	Molecule name	BHp	FC
↑	SLC2A1	GLUT1	7.42E-03	23.26
↑	SLC16A3	MCT4	1.62E-02	14.72
↑	SLC2A3	GLUT3	2.87E-02	12.13
↑	SLC6A8	CT1	8.82E-04	8.74
↑	SLC7A5	LAT1	7.13E-03	8.03
↑	SLC16A1	MCT1	8.54E-03	4.69
↑	SLC39A14	ZIP14	1.15E-02	3.98
↑	SLC15A4	PHT1	4.02E-02	3.08
↑	SLC29A4	ENT4	4.08E-02	2.55
↑	SLC38A5	SN2	3.67E-02	2.20
↓	SLC25A12	ARALAR1	3.42E-02	0.22
↓	SLC11A2	NRAMP2	7.54E-03	0.23
↓	SLC19A3	THTR2	1.75E-02	0.40
↓	SLC35B4	n/a	3.42E-02	0.44

**Suppl. 9: The top up- and top downregulated transporter genes in SGBS adipocytes after 16h of hypoxia.** Members of the upregulated ( ↑ ) as well as downregulated ( ↓ ) genes for transporters of the solute carrier family (SLC) were ranked according to the genes' FC. P-values (BHp) have been calculated according to Benjamini and Hochberg.